Put companies on watchlist
Swiss Re Ltd
ISIN: CH0126881561
WKN: A1H81M
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Swiss Re Ltd · ISIN: CH0126881561 · EQS - Company News (133 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1827083
31 January 2024 10:02AM

a simple blood test has the potential to revolutionise cancer screening


Swiss Re Ltd / Key word(s): Research Update
Multi-cancer early detection tests: a simple blood test has the potential to revolutionise cancer screening

31.01.2024 / 10:02 CET/CEST


  • Multi-cancer early detection (MCED) blood tests have the potential to increase early detection rates of some cancers, improving survivability
  • MCED tests may reduce the costs associated with late-stage cancer treatments; more real-world studies needed to validate their efficacy and applicability in the wider population
  • Concerns around MCEDs include their ability to detect cancers at early stages and the specific cancer site of origin
  • Swiss Re Institute report examines the effectiveness of eight MCED tests under various stages of development, with significant differences in their ability to detect specific cancers

Zurich, 31 January 2024 – Multi-cancer early detection blood tests offer a future where a single blood test can provide a routine, comprehensive screening for a range of cancers. This type of minimally invasive test would be a revolution in the early detection of cancers and has the potential to improve survival rates and decrease the economic burden of late-stage treatments. However, MCEDs are still in the early stages of development. Swiss Re Institute's new report "Multi-Cancer Early Detection: cancer screening beyond today's boundaries", explores the future risks and opportunities for patients and insurers.

Natalie Kelly, Swiss Re’s Head of Global L&H Underwriting, Claims & R&D says: "MCEDs offer us hope of catching cancers at the earliest stages, boosting survival rates and reducing costs by avoiding complicated late-stage treatments. However, given this early stage of their development, we need to carefully examine their potential, their risks, and the implications for insurers."

Early detection to save lives and reduce treatment costs

MCED blood tests are a type of liquid biopsy which can detect cancer biomarkers in a single sample of blood. These minimally invasive blood tests can be effective in detecting cancers at an earlier stage, potentially before patients are symptomatic.

Research indicates that early diagnosis can significantly improve 5-year survival rates for some cancers by 15–25%, if they can be detected before they spread to other parts of the body.[1]

Earlier detection also has the potential to reduce the cost of treating cancer. Cancer Research UK concluded that treatment for certain cancers at stage 3 and 4 cost the UK's National Health Service nearly two and a half times more than the amount spent on treating cancers at stages 1 and 2.[2]

Concerns over missing real-world evidence and potential for inaccurate test results

While the potential to increase survivability is promising, Swiss Re Institute urges caution. Although statistical evidence points to large theoretical gains in survival rates and cost savings, at this early stage of development there are no studies which have validated that potential in a real-world setting. Further, MCED tests currently require clinical validation by conventional diagnostic methods prior to commencing any treatment. There is also a risk of causing distress for patients who are given inaccurate results.

In order to better understand these concerns, Swiss Re Institute's paper examines the effectiveness of eight MCED tests under various stages of development, including some in clinical trials. Swiss Re uncovered significant differences in the current generation of MCED tests, in their ability to detect specific cancers, early and accurately, when treatment options are most likely to be effective. With the speed of medical innovation, all signs point towards the wider deployment of MCED tests, as a complementary tool to existing practices within a decade. 

For insurers, Swiss Re Institute's report examines the impact of widespread adoption of MCED tests and implications for life and health insurance products, particularly life, critical illness, and medical reimbursement covers. It outlines the need to undertake risk assessments to consider potential implications of MCED tests on underwriting guidelines, pricing, claims, product design, and regulatory compliance.

 

How to order this study:

You can download "Multi-Cancer Early Detection: cancer screening beyond today's boundaries" here.

 

Disclaimer
Although all the information discussed herein was taken from reliable sources, Swiss Re does not accept any responsibility for the accuracy or comprehensiveness of the information given or forward-looking statements made. The information provided and forward-looking statements made are for informational purposes only and in no way constitute or should be taken to reflect Swiss Reʼs position, in particular in relation to any ongoing or future dispute. In no event shall Swiss Re be liable for any financial or consequential loss or damage arising in connection with the use of this information and readers are cautioned not to place undue reliance on forward-looking statements. Swiss Re undertakes no obligation to publicly revise or update any forward-looking statements, whether as a result of new information, future events or otherwise.

 


For further information please contact Swiss Re Media Relations: + 41 (0)43 285 7171 or Media_Relations@Swissre.com.
Please use this link to access Swiss Re's press releases.

Swiss Re
The Swiss Re Group is one of the world’s leading providers of reinsurance, insurance and other forms of insurance-based risk transfer, working to make the world more resilient. It anticipates and manages risk – from natural catastrophes to climate change, from ageing populations to cyber crime. The aim of the Swiss Re Group is to enable society to thrive and progress, creating new opportunities and solutions for its clients. Headquartered in Zurich, Switzerland, where it was founded in 1863, the Swiss Re Group operates through a network of around 80 offices globally.

Cautionary note on forward-looking statements
Certain statements and illustrations contained herein are forward-looking. These statements (including as to plans, objectives, targets, and trends) and illustrations provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical fact or current fact. Further information on forward looking statements can be found in the Legal Notice section of Swiss Re's website.



End of Media Release


Language: English
Company: Swiss Re Ltd
Mythenquai 50/60
8022 Zurich
Switzerland
Phone: +41 (0) 43 285 71 71
E-mail: Media_Relations@swissre.com
Internet: www.swissre.com
ISIN: CH0126881561
Valor: 12688156
Listed: SIX Swiss Exchange
EQS News ID: 1827083

 
End of News EQS News Service

1827083  31.01.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1827083&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Swiss Re Ltd
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.